Contract Development & Manufacturing (CDMO):
B-MoGen’s ISO 7 cleanrooms now open for business
B-MoGen Biotechnologies, a unit of Bio-Techne, is proud to announce new cGMP cellular therapy manufacturing capacity for Phase I and Phase II clinical trials.
Minneapolis, June 15, 2020 — Are you looking for a CDMO to process your Phase I/II clinical trials or to manufacture GMP grade engineered mammalian cells? If you need this service now and need it at a reasonable cost, B-MoGen’s new clean room facility became fully operational as of May 1, 2020. B-MoGen now offers process development for any gene modified therapy, cGMP patient processing for Phase I and Phase II clinical trials, and cGMP manufacturing of iPSC cell lines.
B-MoGens state of the art 6,000 square foot cGMP facility is strategically located in Minneapolis, MN, USA. Its US-based suites currently comply with ISO Class 7 (Class 10,000) classification to meet U.S. requirements.
View video footage of the B-MoGen facility:
https://www.youtube.com/watch?v=PJtcLKcFVX8
For more information visit:
https://bmogen.com/gene-engineering/contract-development-manufacturing/
Contact:
Jeff Liter
Telephone: 1.612.309.7653
Email: jeff.liter@bio-techne.com